For many women, completing treatment does not mean the fear of cancer disappears. Even after surgery, chemotherapy, or other therapies, the possibility of recurrence remains a significant concern. The months and years following treatment often bring a new challenge of living with uncertainty while remaining vigilant for signs that the disease may return.
Recurrence is especially common in advanced ovarian cancer despite significant advances in treatment. Women with advanced endometrial cancer may also face the risk of relapse, which can narrow future treatment options. For many, cancer becomes a condition that requires long-term monitoring and management rather than a one-time illness.
Regular consultations, clinical examinations, imaging, and other recommended tests help detect recurrence at the earliest possible stage while also identifying and managing long-term treatment-related complications. Equally important is empowering women to recognise warning signs and adhere to scheduled follow-up appointments, allowing timely intervention when it can make the greatest difference.
Why gynaecological cancers demand long-term vigilance
The need for sustained follow-up has become even more important as the burden of gynaecological cancers continues to grow in India.
Every year, approximately 17,420 new cases of endometrial cancer are reported in India, largely driven by changing lifestyles and reproductive patterns. Rising obesity, urbanisation, early menarche, delayed menopause, and genetic predisposition are contributing to its growing cases. Early detection can significantly improve outcomes, but it’s just as important to stay on track with regular follow-ups after treatment to catch any signs of recurrence and maintain long-term health.
Ovarian cancer presents an even greater challenge because its symptoms, such as bloating, abdominal discomfort, and fatigue, are often vague and easily overlooked. As a result, many women are diagnosed at advanced stages with limited survival outcomes.
Personalising care beyond treatment
Alongside regular surveillance, cancer care is becoming increasingly personalised. While chemotherapy continues to play a central role, treatment strategies are evolving to better reflect the biology of the disease, the risk of recurrence, and each patient's individual needs.
Ultimately, cancer care should not end when treatment does. For women with gynaecological cancers, survivorship is an equally important phase of the journey. Sustained follow-up, greater awareness of recurrence, timely intervention, and personalised care can help women move beyond cancer with greater confidence, better health, and an improved quality of life.
The author is the director, Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre.
The opinions expressed in this article are those of the author and do not purport to reflect the opinions or views of THE WEEK.
